# Study of Temsirolimus, Topotecan, and Bortezomib

> **NCT00770731** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 80 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Torisel (Temsirolimus)
- **DRUG:** Hycamtin (Topotecan)
- **DRUG:** Velcade (Bortezomib)

## Key facts

- **NCT ID:** NCT00770731
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770731, "Study of Temsirolimus, Topotecan, and Bortezomib". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00770731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*